AEs · chronic pain (excluding headache) in adults
1 finding from 1 review
Adverse events – anxiety – after first session – short term · schizophrenia or related disorders
Avatar Therapy showed no clear difference in adverse events – anxiety – after first session – short term compared with treatment (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events the resulted in discontinuation of treatment · adults and children with confirmed clinical and parasitological P vivax malaria
It is very uncertain whether the intervention changes adverse events the resulted in discontinuation of treatment (very low certainty).
1 finding from 1 review
Adverse events (including pain, falls and all‐cause deaths) · People performing gait rehabilitation after stroke
1 finding from 1 review
Adverse events (timing not specified) · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ overall (any adverse events not specified) compared with placebo overall (moderate certainty).
1 finding from 1 review
Non‐serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
533 participants
Very low
Adverse events associated with RIC treatment ‐ not reported · people with ischaemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ conjunctival blanching during study period · people with glaucoma receiving LTP
1 finding from 1 review
Adverse reaction: apnoea and hypoglycaemia Number of events · neonates receiving EBT
1 finding from 1 review
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Adverse eventsAssessed rejection episodes of lung transplant · adult lung transplant recipients
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Total serious adverse events№ of participants: 18165(6 RCTs) · adult patients with hypertension
Lower BP target showed no clear difference in total serious adverse events№ of participants: 18165(6 RCTs) compared with standard BP target (moderate certainty).
1 finding from 1 review
RR 1.04 [0.99, 1.08]
Studies not reported
Moderate
Adverse events ‐ Miscarriage · women with subfertility
Antioxidant(s) showed no clear difference in adverse events ‐ Miscarriage№ of participants: 3229(24 RCTs) compared with placebo or no treatment/standard treatment (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review